Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
46.02
-0.77 (-1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharma
< Previous
1
2
3
4
5
6
7
Next >
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
November 01, 2023
Via
ACCESSWIRE
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
September 13, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
August 08, 2023
Via
ACCESSWIRE
Amphastar Pharma: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
May 09, 2023
Via
ACCESSWIRE
Earnings Outlook For Amphastar Pharma
May 08, 2023
Via
Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 11, 2023
Via
Benzinga
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
September 11, 2023
Via
ACCESSWIRE
Lilly to Divest BAQSIMI to Amphastar
April 24, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
August 31, 2023
Via
ACCESSWIRE
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
August 17, 2023
Eli Lilly and Company (LLY) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer.
Via
Talk Markets
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
August 02, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
June 30, 2023
Via
ACCESSWIRE
Promising Small Biotech Amphastar Sees Actionable Pullback
June 28, 2023
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views.
Via
MarketBeat
Abcam Stock Earns Relative Strength Rating Upgrade
June 20, 2023
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.
Via
Investor's Business Daily
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
June 20, 2023
Via
Investor Brand Network
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
June 06, 2023
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.
Via
Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
May 03, 2023
Via
ACCESSWIRE
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
May 03, 2023
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.
Via
Investor's Business Daily
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
April 24, 2023
Via
Benzinga
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
April 24, 2023
Via
ACCESSWIRE
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.